ASH 2021 | Venetoclax based combination therapy in AML: a real-world retrospective analysis
Prapti Patel, MD, University of Texas Southwestern Medical Center, Dallas, TX, discusses a real-world retrospective analysis which aimed to see if results obtained from patients with acute myeloid leukemia (AML) treated with frontline venetoclax-based combination therapy corresponded with results from the VIALE-A trial (NCT02993523). Using the COTA database, Dr Patel explains the selection of patients in this study, and the treatment groups that were used: hypomethylating agent (HMA) backbone plus venetoclax, or cytarabine plus venetoclax. Following this, Dr Patel discusses the response criteria and some fallbacks in the data used in this analysis, and then goes on to explain the main results obtained, comparing these findings to those reported in the VIALE-A trial. To conclude, Dr Patel comments on the toxicity observed in these treatment regimens, and how this limits the effectiveness of long-term dosing. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
Disclosures
BMS-Celgene, Agios: Membership on an entity’s Board of Directors or advisory committees; Peerview: Honoraria.
